Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Physicians Seek Unrestricted Coverage Of NaF-18 PET For Bone Metastasis

This article was originally published in The Gray Sheet

Executive Summary

Recent shortages of an isotope commonly used in bone scans have prompted several professional societies to urge CMS to offer cancer patients broad access to sodium fluoride-18 positron emission tomography to identify bone metastasis

You may also be interested in...



CMS Proposes Coverage With Study Participation For PET In Bone Metastasis

CMS is proposing to cover positron emission tomography imaging for identification of bone metastasis in patients with a previously diagnosed solid tumor, but only as part of prospective clinical trials, the agency announced Nov. 30

Oncology PET Scan Coverage Expands As CMS Lifts Some Data Mandates

Medicare coverage of PET scans for oncology indications will be less restrictive under a national coverage determination finalized April 3

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

Topics

UsernamePublicRestriction

Register

MT028363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel